Johnson & Johnson Operating Expenses 2012-2026 | JNJ
Johnson & Johnson annual/quarterly operating expenses history and growth rate from 2012 to 2026. Operating expenses can be defined as the sum of all operating expenses for the given industry.
- Johnson & Johnson operating expenses for the quarter ending March 31, 2026 were $18.072B, a 118.74% increase year-over-year.
- Johnson & Johnson operating expenses for the twelve months ending March 31, 2026 were $71.422B, a 13.86% increase year-over-year.
- Johnson & Johnson annual operating expenses for 2025 were $61.612B, a 14.59% decline from 2024.
- Johnson & Johnson annual operating expenses for 2024 were $72.134B, a 2.91% increase from 2023.
- Johnson & Johnson annual operating expenses for 2023 were $70.097B, a 15.61% increase from 2022.
|
Johnson & Johnson Annual Operating Expenses (Millions of US $) |
|
|---|---|
| 2025 | $61,612 |
| 2024 | $72,134 |
| 2023 | $70,097 |
| 2022 | $60,631 |
| 2021 | $59,562 |
| 2020 | $66,087 |
| 2019 | $64,731 |
| 2018 | $63,582 |
| 2017 | $58,777 |
| 2016 | $52,087 |
| 2015 | $50,878 |
| 2014 | $53,768 |
| 2013 | $55,841 |
| 2012 | $53,449 |
| 2011 | $52,669 |
|
Johnson & Johnson Quarterly Operating Expenses (Millions of US $) |
|
|---|---|
| 2026-03-31 | $18,072 |
| 2025-12-31 | $19,598 |
| 2025-09-30 | $16,500 |
| 2025-06-30 | $17,252 |
| 2025-03-31 | $8,262 |
| 2024-12-31 | $18,633 |
| 2024-09-30 | $19,133 |
| 2024-06-30 | $16,699 |
| 2024-03-31 | $17,669 |
| 2023-12-31 | $16,569 |
| 2023-09-30 | $16,134 |
| 2023-06-30 | $15,213 |
| 2023-03-31 | $22,181 |
| 2022-12-31 | $10,063 |
| 2022-09-30 | $14,824 |
| 2022-06-30 | $18,180 |
| 2022-03-31 | $17,564 |
| 2021-12-31 | $8,531 |
| 2021-09-30 | $19,489 |
| 2021-06-30 | $16,650 |
| 2021-03-31 | $14,892 |
| 2020-12-31 | $20,828 |
| 2020-09-30 | $16,681 |
| 2020-06-30 | $14,396 |
| 2020-03-31 | $14,182 |
| 2019-12-31 | $16,529 |
| 2019-09-30 | $19,082 |
| 2019-06-30 | $13,521 |
| 2019-03-31 | $15,599 |
| 2018-12-31 | $17,272 |
| 2018-09-30 | $15,925 |
| 2018-06-30 | $15,857 |
| 2018-03-31 | $14,528 |
| 2017-12-31 | $17,635 |
| 2017-09-30 | $14,860 |
| 2017-06-30 | $14,091 |
| 2017-03-31 | $12,191 |
| 2016-12-31 | $13,782 |
| 2016-09-30 | $12,539 |
| 2016-06-30 | $13,578 |
| 2016-03-31 | $12,188 |
| 2015-12-31 | $14,053 |
| 2015-09-30 | $12,980 |
| 2015-06-30 | $12,046 |
| 2015-03-31 | $11,799 |
| 2014-12-31 | $15,551 |
| 2014-09-30 | $11,657 |
| 2014-06-30 | $13,869 |
| 2014-03-31 | $12,691 |
| 2013-12-31 | $15,605 |
| 2013-09-30 | $13,908 |
| 2013-06-30 | $13,084 |
| 2013-03-31 | $13,244 |
| 2012-12-31 | $14,458 |
| 2012-09-30 | $13,457 |
| 2012-06-30 | $14,440 |
| 2012-03-31 | $11,094 |
| 2011-12-31 | $15,937 |
| 2011-09-30 | $11,894 |
| 2011-06-30 | $13,175 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |